A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia¹

• Main Authors: Chutima Kunacheewa, Pakaporn Thongthang, Patompong Ungprasert, Eakkapol Utchariyaprasit, Weerapat Owattanapanich
• 其他作者: Faculty of Medicine, Siriraj Hospital, Mahidol University
• 格式: Article
• 出版: 2020
• 主題: Medicine
• 在線閱讀: https://repository.li.mahidol.ac.th/handle/123456789/52102

© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Objectives: The addition of lenalidomide (LEN) to azacitidine (AZA) may further improve the outcomes of acute myeloid leukemia (AML) patients as well as patients with high-risk myelodysplastic syn...